Webinar | March 3, 2022

Human ADME Studies: Leveraging A Synthesis-To-Clinic® Approach To Rapidly Support Regulatory Approval

Source: Quotient Sciences

In this webinar, Iain Shaw, Senior Director of 14C Enabled Drug Development at Quotient Sciences, is joined by a panel of experts from our drug development, radiosynthesis and clinical pharmacology teams to answer questions around strategies for efficient human ADME study design. The benefits of leveraging a synthesis-to-clinic approach to rapidly support regulatory approval are discussed.

access the Webinar!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Quotient Sciences